ALBRIOZA Commercial Launch

Focused Priorities Helping people gain access to RELYVRIOⓇ in the U.S. and ALBRIOZATM in Canada, bringing a much-needed new treatment option to people with ALS I+I ALBRIOZA Launch in Canada Commercial RELYVRIO Commercial Launch in U.S. * Amylyx intends to seek re-examination of the negative CHMP opinion as announced on June 23, 2023. Final CHMP Opinion expected Fall 2023 with decision in late Q4'23 at the earliest* AMYLYX 37

View entire presentation